|
Compound class:
Antibody
Comment: Tizetatug rezetecan (SHR-A1921) is an antibody-drug conjugate (ADC) that is composed of a humanized anti-TROP2 IgG1 monoclonal antibody attached to a DNA topoisomerase I by a cleavable linker. TROP2 is encoded by the TACSTD2 (tumor associated calcium signal transducer 2) gene. The TROP2 protein is overexpressed on the surface of many solid tumour types, and is an active therapeutic target for the development of anti-neoplastics. Sacituzumab govitecan (Trodelvy®) was the first monoclonal in this class to be approved by the FDA (in 2020).
|
| No information available. |
Summary of Clinical Use  |
| Tizetatug rezetecan (SHR-A1921) is a clinical candidate for the treatment of advanced solid tumours. Planned trials will evaluate this agent as a monotherapy and in combination with other anti-tumour therapies with different modes of action. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06394492 | SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer | Phase 3 Interventional | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | ||
| NCT06649331 | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer | Phase 2 Interventional | Fudan University | ||
